Skip to main content

Table 1 Baseline clinical profile of the entire cohort

From: Blood consumption in total arterial coronary artery bypass grafting

Variable

Entire cohort

N = 595

Total arterial CABG

N = 419 (70.4%)

Mixed CABG

N = 176 (29.6%)

p value

Male

501 (84.2%)

360 (85.9%)

141 (80.1%)

0.08

Age (y)

66.1 ± 9.5

66.0 ± 9.5

66.5 ± 9.5

0.55

  < 60

139 (23.4%)

100 (23.9%)

39 (22.2%)

 60–69

230 (38.7%)

167 (39.9%)

63 (35.8%)

 70–79

186 (31.3%)

124 (29.6%)

62 (35.2%)

  ≥ 80

40 (6.7%)

28 (6.7%)

12 (6.8%)

Diabetes

162 (27.2%)

105 (25.1%)

57 (32.4%)

0.016

Hypertension

427 (71.8%)

299 (71.4%)

128 (72.7%)

0.07

Obesity (BMI > 30 kg/cm2)

197 (33.1%)

139 (33.2%)

58 (32.9%)

0.58

Dyslipidemia

385 (64.7%)

275 (65.6%)

110 (62.5%)

0.67

Preoperative hemoglobin

13.2 ± 1.8

13.3 ± 1.7

13.0 ± 1.8

0.07

Preoperative LVEF

52.0 ± 13.1

54.5 ± 11.8

45.7 ± 14.2

< 0.001

Anticoagulation and antiaggregation

 No anticoagulation or antiaggregation

48 (8.1%)

36 (8.6%)

12 (6.8%)

0.60

 Acetylsalicylic acid

498 (83.7%)

359 (85.7%)

139 (79.0%)

0.61

 ADP receptor inhibitors

121 (20.3%)

87 (20.8%)

34 (19.3%)

0.96

 Vitamin K antagonists

9 (1.5%)

5 (1.2%)

4 (2.3%)

0.28

 Factor Xa inhibitors

12 (2.0%)

6 (1.4%)

6 (3.4%)

0.09

 GPIIb/IIIa inhibitors

26 (4.4%)

19 (4.5%)

7 (4.0%)

0.87

No. of distal anastomoses

3.4 ± 1.0

3.1 ± 0.9

3.9 ± 0.9

< 0.001

 2

127 (21.3%)

117 (27.9%)

10 (5.7%)

 3

221 (37.1%)

170 (40.6%)

51 (29.0%)

 4

168 (28.2%)

96 (22.9%)

72 (40.9%)

 5

70 (11.8%)

34 (8.1%)

36 (20.5%)

 6

9 (1.5%)

2 (0.5%)

7 (4.0%)

Crossclamp time (min)

78.2 ± 27.8

79.0 ± 28.9

76.2 ± 25.2

0.25

Composite grafting

208 (35.0%)

200 (47.7%)

8 (4.5%)

< 0.001

  1. LVEF left ventricular ejection fraction